Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 12,402,000 | 8,691,000 | 6,899,000 | 2,501,000 | -265,000 |
| Depreciation Amortization | 5,733,000 | 6,688,000 | 5,387,000 | 5,480,000 | 6,530,000 |
| Accounts receivable | -1,728,000 | -1,624,000 | -1,425,000 | -1,349,000 | -961,000 |
| Accounts payable and accrued liabilities | 1,346,000 | 862,000 | 2,394,000 | 1,165,000 | 1,405,000 |
| Other Working Capital | -1,137,000 | -893,000 | 300,000 | 3,757,000 | 2,021,000 |
| Other Operating Activity | -2,041,000 | -1,863,000 | -3,210,000 | -1,746,000 | -2,767,000 |
| Operating Cash Flow | $14,575,000 | $11,861,000 | $10,345,000 | $9,808,000 | $5,963,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 131,000 | 30,000 | 97,000 | -114,000 | 96,000 |
| PPE Investments | -2,797,000 | -1,869,000 | -1,229,000 | -809,000 | -1,078,000 |
| Net Acquisitions | -1,230,000 | -3,779,000 | -1,015,000 | -48,000 | -9,263,000 |
| Purchase Of Investment | -239,000 | -254,000 | -216,000 | -71,000 | -184,000 |
| Sale Of Investment | N/A | 91,000 | 32,000 | 42,000 | 785,000 |
| Purchase Sale Intangibles | -2,959,000 | -2,539,000 | -2,126,000 | -1,033,000 | -522,000 |
| Other Investing Activity | -2,673,000 | -2,199,000 | -1,733,000 | -1,960,000 | -1,414,000 |
| Investing Cash Flow | $-6,808,000 | $-7,980,000 | $-4,064,000 | $-2,960,000 | $-11,058,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 364,000 | -31,000 | 161,000 | 74,000 | -276,000 |
| Debt Issued | 15,000 | 6,492,000 | 3,816,000 | N/A | 12,929,000 |
| Debt Repayment | -2,029,000 | -4,652,000 | -4,942,000 | -1,271,000 | -4,759,000 |
| Common Stock Issued | 40,000 | 38,000 | 33,000 | 29,000 | 29,000 |
| Common Stock Repurchased | -521,000 | -81,000 | N/A | N/A | N/A |
| Dividend Paid | -4,971,000 | -4,629,000 | -4,481,000 | -4,364,000 | -3,856,000 |
| Other Financing Activity | -442,000 | -1,133,000 | -1,154,000 | -1,291,000 | -418,000 |
| Financing Cash Flow | $-7,544,000 | $-3,996,000 | $-6,567,000 | $-6,823,000 | $3,649,000 |
| Exchange Rate Effect | 46,000 | -93,000 | -60,000 | -80,000 | -62,000 |
| Beginning Cash Position | 5,429,000 | 5,637,000 | 5,983,000 | 6,038,000 | 7,546,000 |
| End Cash Position | 5,698,000 | 5,429,000 | 5,637,000 | 5,983,000 | 6,038,000 |
| Net Cash Flow | $269,000 | $-208,000 | $-346,000 | $-55,000 | $-1,508,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 14,575,000 | 11,861,000 | 10,345,000 | 9,808,000 | 5,963,000 |
| Capital Expenditure | -2,810,000 | -1,924,000 | -1,361,000 | -1,091,000 | -1,091,000 |
| Free Cash Flow | 11,765,000 | 9,937,000 | 8,984,000 | 8,717,000 | 4,872,000 |